X

Drug Profile

Research programme: cognitive disorders therapeutics - Targacept/AstraZeneca

Latest Information Update: 07 Mar 2013

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Targacept
Developer AstraZeneca; Targacept
Class
Mechanism of Action Alpha4 beta2 nicotinic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No

Highest Development Phases

Discontinued Cognition disorders

Most Recent Events

05 Mar 2013 AstraZeneca and Targacept amend collaboration agreement to include all therapeutic areas
09 Dec 2008 Preclinical development is ongoing
13 Dec 2007 Preclinical development is ongoing

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com